Historic biopharma investments: A prescription for America’s future

30 September 2025

President Donald Trump has called on US industries to put America first, and the biopharmaceutical sector is answering that call with major actions to demonstrate its commitment to American patients and workers.

According to a blog posting by trade group Pharmaceutical Research and Manufacturers of America, PhRMA member companies are delivering $500 billion in new USA-based manufacturing and infrastructure investment, injecting an estimated $1.2 trillion into the economy. For every $1 invested by the industry, another $1.60 is spent in other areas of the economy, creating a ripple effect.

These investments will create more than 100,000 jobs - including 25,000 biopharma facility jobs - seizing on President Trump’s tax law changes and regulatory streamlining that make it more attractive to invest in the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK